( PRINCETON N.J.--(BUSINESS WIRE)--Mar 2...)Preclinical Data on Cytogen's Technology to be Reported at the AACR,Annual Meeting,Health

PRINCETON, N.J.--(BUSINESS WIRE)--Mar 29, 2007 - Cytogen Corporation (NASDAQ: CYTO) today reported the upcoming presentation of preclinical data at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) taking place in Los Angeles, California April 14-18, 2007. The AACR abstracts are based on preclinical studies that validate novel approaches to drug discovery and development embodied in the Company's proprietary Abtides(TM) (Antigen-Binding pepTIDES) and oral drug delivery platforms. These data represent a broad scope of findings from in vitro (cell line) and in vivo (animal) experiments.

While Cytogen's internal research and development initiatives focus on clinical-stage opportunities, the Company complements its internal programs with an active business development strategy, which includes capitalizing on the promising proprietary technology platforms previously developed through its AxCell BioSciences research-stage subsidiary. In view of recent biological validation, as well as the progress of internal data mining efforts and external research collaborations, Cytogen is exploring strategic transactions for AxCell BioSciences and will be presenting at the 9th Annual C21 BioVentures Conference (C21) taking place in Monterey, California May 22-24, 2007. -0-

Additional details for the AACR presentations are as follows:


     Presentation Date and Time: Sunday, April 15, 2007,

                                 8:00 AM -12:00 PM

     Abstract #645: Studies with long random phage libraries:

     Epitope-specific peptides recapitulate antibody complementarity

     determining regions (CDRs) of PSMA and MUC-1 antibodies and PSMA

     binding peptides target prostate xenografts.


     Presentation Date and Time: Sunday, April 15, 2007,

                                 1:00 PM - 5:00 PM

     Abstract #1497: Oral delivery of leuprolide in a rat model using

     poly-lactide-glycolic acid (PLGA) nanoparticles coated with

     
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial
Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab
Binds to the EGF Receptor and Potentiates Radiotherapy
4. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data
Presented at International Myeloma Workshop
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical
Model
6. Publication on Pixantrone Preclinical Studies Demonstrates Reduced
Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and
Mitoxantrone
7. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for
the Treatment of Obesity at the American Diabetes Association 67th
Scientific Session
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its
Ghrelin Antagonist Program at the American Diabetes Associations
Annual Meeting
9. Genaera to Present Preclinical Data on Trodusquemine for the
Treatment of Obesity at the American Diabetes Association 67th
Scientific Sessions
10. Metabasis Therapeutics Presents Results of Preclinical Studies for
MB07811, Its Novel Product Candidate for the Treatment of
Hyperlipidemia, at the Endocrine Societys Annual Meeting
11. Elixir Pharmaceuticals Presents Additional Preclinical Data
Demonstrating the Potential of Ghrelin Antagonism to Regulate
Metabolism, Body Weight and Glycemic Control